IL233928A0 - A pluripotent germ layer-derived antigen with anti-cancer properties - Google Patents
A pluripotent germ layer-derived antigen with anti-cancer propertiesInfo
- Publication number
- IL233928A0 IL233928A0 IL233928A IL23392814A IL233928A0 IL 233928 A0 IL233928 A0 IL 233928A0 IL 233928 A IL233928 A IL 233928A IL 23392814 A IL23392814 A IL 23392814A IL 233928 A0 IL233928 A0 IL 233928A0
- Authority
- IL
- Israel
- Prior art keywords
- antigen presenting
- cancer vaccine
- germ layer
- pluripotent germ
- presenting cancer
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title 1
- 102000036639 antigens Human genes 0.000 title 1
- 108091007433 antigens Proteins 0.000 title 1
- 229940022399 cancer vaccine Drugs 0.000 title 1
- 238000009566 cancer vaccine Methods 0.000 title 1
- 210000001654 germ layer Anatomy 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/19—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/24—Antigen-presenting cells [APC]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4244—Enzymes
- A61K40/4245—Tyrosinase or tyrosinase related proteinases [TRP-1 or TRP-2]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K40/4268—MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4271—Melanoma antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4271—Melanoma antigens
- A61K40/4272—Melan-A/MART
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/876—Skin, melanoma
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261594304P | 2012-02-02 | 2012-02-02 | |
| PCT/US2013/024123 WO2013116505A1 (en) | 2012-02-02 | 2013-01-31 | Pluripotent germ layer origin antigen presenting cancer vaccine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL233928A0 true IL233928A0 (en) | 2014-09-30 |
Family
ID=48905824
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL233928A IL233928A0 (en) | 2012-02-02 | 2014-08-03 | A pluripotent germ layer-derived antigen with anti-cancer properties |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20150064217A1 (enExample) |
| EP (1) | EP2809775B1 (enExample) |
| JP (1) | JP2015506698A (enExample) |
| KR (1) | KR20140143361A (enExample) |
| CN (1) | CN104540937A (enExample) |
| AU (1) | AU2013215116A1 (enExample) |
| CA (1) | CA2863653A1 (enExample) |
| GB (1) | GB2512558A (enExample) |
| HK (2) | HK1209455A1 (enExample) |
| IL (1) | IL233928A0 (enExample) |
| NZ (1) | NZ628292A (enExample) |
| SG (1) | SG11201404543UA (enExample) |
| WO (2) | WO2013116541A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103599528B (zh) * | 2013-12-04 | 2015-08-05 | 深圳市合一康生物科技股份有限公司 | 人树突状细胞疫苗的制备方法 |
| JP6423889B2 (ja) | 2014-10-07 | 2018-11-14 | サイトリミック株式会社 | Ｈｓｐ７０由来のペプチド、これを用いた癌の治療又は予防のための医薬組成物、免疫誘導剤、及び抗原提示細胞の製造方法 |
| EP3527216B1 (en) | 2016-10-11 | 2024-02-14 | NEC Corporation | A medicine comprising a toll-like receptor agonist, lag-3 protein, a hsp70-derived peptide and a gpc3-derived peptide |
| CN110198717A (zh) * | 2017-01-11 | 2019-09-03 | 国立研究开发法人国立癌症研究中心 | 免疫治疗药 |
| EP3582793A4 (en) * | 2017-02-17 | 2020-12-16 | Aivita Biomedical, Inc. | METHODS TO IMPROVE TUMOR IMMUNOGENICITY AND COMPOSITIONS FOR AUTOLOGOUS ANTI-CANCER IMMUNOTHERAPEUTICS USING MODIFIED TUMOR CELLS AND MODIFIED DENDRITIC CELLS |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL140796A0 (en) * | 2001-01-08 | 2002-02-10 | Hadasit Med Res Service | An autologous anti-cancer vaccine |
| EP2322603B1 (en) * | 2001-09-06 | 2019-10-16 | NorthWest Biotherapeutics, Inc. | Compositions and methods for priming monocytic dendritic cells and T cells for Th1 response |
| WO2006047515A2 (en) * | 2004-10-25 | 2006-05-04 | Baylor Research Institute | Dendritic cells loaded with heat shocked melanoma cell bodies |
| JP5281399B2 (ja) * | 2005-07-29 | 2013-09-04 | プロビデンス ヘルス システム | 小胞（ｄｒｉｂｂｌｅ）中の不完全なリボソーム産物、および免疫応答を刺激するための使用方法 |
| WO2008039974A2 (en) * | 2006-09-28 | 2008-04-03 | Cedars-Sinai Medical Center | Cancer vaccines and vaccination methods |
| US20090041792A1 (en) * | 2007-07-19 | 2009-02-12 | Istituto Superiore Di Sanita | Dendritic cells, uses therefor, and vaccines and methods comprising the same |
-
2013
- 2013-01-31 CN CN201380017689.2A patent/CN104540937A/zh active Pending
- 2013-01-31 HK HK15110097.4A patent/HK1209455A1/xx unknown
- 2013-01-31 NZ NZ628292A patent/NZ628292A/en not_active IP Right Cessation
- 2013-01-31 GB GB1414403.4A patent/GB2512558A/en not_active Withdrawn
- 2013-01-31 CA CA2863653A patent/CA2863653A1/en not_active Abandoned
- 2013-01-31 EP EP13743673.9A patent/EP2809775B1/en not_active Not-in-force
- 2013-01-31 KR KR1020147024678A patent/KR20140143361A/ko not_active Ceased
- 2013-01-31 US US14/375,966 patent/US20150064217A1/en not_active Abandoned
- 2013-01-31 HK HK15103009.6A patent/HK1202432A1/xx unknown
- 2013-01-31 SG SG11201404543UA patent/SG11201404543UA/en unknown
- 2013-01-31 WO PCT/US2013/024181 patent/WO2013116541A1/en not_active Ceased
- 2013-01-31 WO PCT/US2013/024123 patent/WO2013116505A1/en not_active Ceased
- 2013-01-31 AU AU2013215116A patent/AU2013215116A1/en not_active Abandoned
- 2013-01-31 JP JP2014555705A patent/JP2015506698A/ja active Pending
-
2014
- 2014-08-03 IL IL233928A patent/IL233928A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2013116505A1 (en) | 2013-08-08 |
| GB201414403D0 (en) | 2014-10-01 |
| CN104540937A (zh) | 2015-04-22 |
| SG11201404543UA (en) | 2014-08-28 |
| US20150064217A1 (en) | 2015-03-05 |
| NZ628292A (en) | 2016-09-30 |
| EP2809775A4 (en) | 2015-07-01 |
| HK1202432A1 (en) | 2015-10-02 |
| GB2512558A (en) | 2014-10-01 |
| KR20140143361A (ko) | 2014-12-16 |
| CA2863653A1 (en) | 2013-08-08 |
| HK1209455A1 (en) | 2016-04-01 |
| EP2809775A1 (en) | 2014-12-10 |
| EP2809775B1 (en) | 2018-06-13 |
| WO2013116541A1 (en) | 2013-08-08 |
| AU2013215116A1 (en) | 2014-08-21 |
| JP2015506698A (ja) | 2015-03-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201500784B (en) | Mycobacterial antigen vaccine | |
| IL235890A0 (en) | vaccine | |
| SG10201610251PA (en) | Compositions and methods for cancer immunotherapy | |
| ZA201306944B (en) | Individualized vaccines for cancer | |
| GB201223386D0 (en) | Vaccine | |
| SG11201500396TA (en) | Tumor vaccination | |
| SG10201508535RA (en) | Antigen Presenting Cancer Vaccine | |
| GB201003293D0 (en) | Cancer vaccine | |
| IL233928A0 (en) | A pluripotent germ layer-derived antigen with anti-cancer properties | |
| SMT201900521T1 (it) | Vaccini individualizzati per il cancro | |
| PL2591798T3 (pl) | Szczepionka do zastosowania w immunoterapii nowotworów | |
| ZA201407309B (en) | Antigens and antigen combinations | |
| GB201210226D0 (en) | Vaccine | |
| GB201202090D0 (en) | Vaccine | |
| GB201107549D0 (en) | Cancer vaccine | |
| GB201217321D0 (en) | Vaccine | |
| GB201206169D0 (en) | Vaccine | |
| GB201205599D0 (en) | Vaccine | |
| GB201207385D0 (en) | Antigens and antigen combinations | |
| GB201207383D0 (en) | Antigens and antigen combinations | |
| GB201216749D0 (en) | Antigen combinations | |
| GB201200568D0 (en) | Antigen combinations |